SearchDictionaryMobileLogin

Markku S Nieminen Selected Research

Hypertension (High Blood Pressure)

06/2008Left bundle branch block and cardiovascular morbidity and mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension study.
02/2007Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
05/2006Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study.
01/2006Electrocardiographic strain pattern and prediction of new-onset congestive heart failure in hypertensive patients: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study.
11/2005Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
11/2005Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.
09/2005The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension taking aspirin: the Losartan Intervention for Endpoint Reduction in hypertension (LIFE) study.
04/2005Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.
04/2005Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.
03/2005Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
03/2005The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.
03/2005Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.
02/2005Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study.
01/2005Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
09/2004Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial.
09/2004Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy.
05/2004QRS duration and QT interval predict mortality in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention for Endpoint Reduction in Hypertension Study.
08/2003Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study.
04/2003An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.
12/2002Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
09/2002Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy.
09/2002Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study.
07/2002Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
03/2002Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
03/2002Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Articles by Research Topic

Disease

25Hypertension (High Blood Pressure)
06/2008 - 03/2002
12Left Ventricular Hypertrophy (Ventricular Hypertrophy, Left)
06/2008 - 09/2002
6Heart Failure
04/2008 - 06/2002
5Coronary Artery Disease (Coronary Atherosclerosis)
05/2008 - 03/2002
3Albuminuria
11/2005 - 09/2004
3Stroke (Strokes)
03/2005 - 01/2005
3Dilated Cardiomyopathy (Cardiomyopathy, Congestive)
12/2004 - 12/2003
2Infection
01/2008 - 07/2007
2Sclerosis
11/2005 - 10/2004
2Atrial Fibrillation
03/2005 - 03/2005
2Coronary Disease (Coronary Heart Disease)
04/2004 - 03/2002
1Bundle-Branch Block (Fascicular Block)
06/2008
1Periodontitis
10/2006
1Cardiomegaly (Heart Hypertrophy)
01/2005
1Respiratory Tract Infections (Respiratory Tract Infection)
05/2004
1Vascular Diseases (Vascular Disease)
08/2003
1Myocardial Ischemia (Ischemic Heart Diseases)
06/2003
1Atherosclerosis (Atheroma)
05/2003
1Myocardial Infarction
03/2003
1Hypertrophy
07/2002
1Syndrome
04/2002

Drug/Important Bio-Agent (IBA)

28Losartan (Cozaar)FDA Link
06/2008 - 03/2002
13Atenolol (Tenormin)FDA LinkGeneric
09/2005 - 03/2002
2simendan (Levosimendan)IBA
05/2007 - 05/2003
2Clarithromycin (Biaxin)FDA LinkGeneric
10/2006 - 04/2002
1ApolipoproteinsIBA
05/2008
1CytokinesIBA
04/2008
1HLA-B Antigens (HLA-B)IBA
01/2008
1pro-brain natriuretic peptide (1-76)IBA
08/2007
1Anti-Bacterial Agents (Antibiotics)IBA
07/2007
1DobutamineFDA LinkGeneric
05/2007
1Aryldialkylphosphatase (Paraoxonase)IBA
06/2006
1Hemoglobins (Hemoglobin)IBA
05/2006
1Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
11/2005
1AngiotensinsIBA
11/2005
1Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
09/2005
1Angiotensin Receptors (Angiotensin II Receptor)IBA
03/2005
1Ventricular MyosinsIBA
12/2004
1Lamin Type A (Lamin A)IBA
05/2004
1Lipoproteins (Lipoprotein)IBA
04/2004
1HomocysteineIBA
02/2004
1Gemfibrozil (Lopid)FDA LinkGeneric
02/2004
1Sarcoglycans (beta Sarcoglycan)IBA
12/2003
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2003
1CD31 AntigensIBA
05/2003
1CholesterolIBA
04/2003
1omapatrilatIBA
03/2003
1TNFR-Fc fusion protein (etanercept)FDA Link
06/2002
1PPAR alphaIBA
03/2002
1Endothelin-converting enzyme 1IBA
03/2002
1Tissue Plasminogen Activator (Alteplase)FDA Link
03/2002

Therapy/Procedure

1Transplantation (Transplant Recipients)
05/2004
1Stents
06/2003